State to Receive $12 Million in Pharmaceutical Settlement

Tennessee will receive more than $12 million as part of a multistate and federal settlement agreement resolving allegations that pharmaceutical manufacturer Johnson & Johnson used deceptive marking tactics to promote the sale of two of its drugs, Risperdal and Invega. According to a news release by the State Attorney General’s office, Johnson & Johnson and its subsidiary, Janssen Pharmaceuticals, will pay in excess of $1.2 billion. In addition, Janssen will plead guilty in federal court to a criminal misdemeanor charge of misbranding Risperdal in violation of the Food, Drug, and Cosmetic Act.